FRONTIER BIOTECHNOLOGIES Inc.

News

FRONTIER BIOTECHNOLOGIES Inc
Home>News>Themed Speech of Frontier Biotechnologies Founder Dr. Xie Dong at 2016 HIV Medicine Therapy Conference in Glasgow, UK

Themed Speech of Frontier Biotechnologies Founder Dr. Xie Dong at 2016 HIV Medicine Therapy Conference in Glasgow, UK

  • 2017-01-17  10:54:33

2016 HIV Medicine Therapy Conference was held in Glasgow, UK from October 23 to 26. Dr. Dong Xie, founder of Frontier Biotech and Chief Scientist, was invited to address a TALENT research themed speech. TALENT study is phase III of the first licensing study of a new antiretroviral drug conducted in China.. The study randomised 389 treatment-experienced individuals who had experienced virological failure of a first-line regimen to receive either a weekly infusion of albuvirtide (dose unspecified) plus twice-daily dosing of the boosted protease inhibitor lopinavir/ritonavir, or a regimen of lopinavir/ritonavir twice daily plus two NRTIs: lamivudine and either tenofovir, abacavir or zidovudine, depending on previous treatment history (72% received tenofovir, 26% zidovudine, 1% abacavir and 1% tenofovir and zidovudine). The protocol-specified interim analysis took place when half of the target recruitment had completed 48 weeks of treatment. At 48 weeks 80.4% of the albuvirtide group had viral load below 50 copies/ml by intent-to-treat analysis, compared to 66% in the triple-drug group. The albuvirtide arm was non-inferior to the standard triple-drug regimen in second-line treatment.No resistance to albuvirtide was detected in the five individuals who had viral load above 500 copies/ml. Moreover, Albuvirtide was verified to be well tolerated.

Innovative solutions to promote human health